Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Melanoma, Cutaneous Malignant 1Glioblastoma 1Colonic Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 97130-nm albumin-bound paclitaxel 47Albumin-Bound Paclitaxel 36Oxaliplatin 27Fluorouracil 26Capecitabine 20Taxes 19Leucovorin 19pembrolizumab 18Cyclophosphamide 18Irinotecan 16Bevacizumab 12fludarabine 11Nivolumab 11Cetuximab 11Cisplatin 10durvalumab 8Radiotherapy 8spartalizumab 7aldesleukin 7Erlotinib Hydrochloride 7Drug Therapy 7avelumab 6Radiosurgery 6Paclitaxel 6irinotecan sucrosofate 5folfirinox 5Ipilimumab 5Injections 5ALT-803 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Neoplasms × nintedanib × Clear all
NCT02902484 2024-06-03

Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Terminated
14 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡